This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Andrew Butcher describes why securing stakeholder buy-in to high-cost new therapies is critical to managing the pharmaceutical industry’s reputation in the November/December 2015 issue of PharmaVOICE. To read more, click here.
Europe’s health systems are facing growing pressure amidst strained public budgets, ageing populations, and increasing treatment costs, prompting urgent questio
Advances in neuroscience are reshaping our understanding of the brain and opening new frontiers in how we diagnose, treat, and ultimately prevent neurological...
CRA is a proud supporter of the Healthcare Businesswomen’s Association (HBA) and sponsor of the HBA Boston-Cambridge Metro chapter event hosting author and...
CRA is a proud sponsor of the first-ever GAR Live: Life Sciences, evolving from the much-loved Technology Disputes event to reflect the growing complexity and...
